The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder

Steven J. Garlow, Boadie W. Dunlop, Philip T. Ninan, Charles Nemeroff

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: To determine whether the combination of triiodothyronine (T3) plus sertraline at treatment initiation confers greater antidepressant efficacy than sertraline plus placebo in patients with major depressive disorder. Method: Eight-week, double blind, randomized placebo controlled clinical trial of 153 adult outpatients between 18 and 60 years of age, with DSM-IV defined major depressive disorder. Patients were treated with sertraline flexibly adjusted for tolerability and in a double blind fashion with placebo or T3 (25 μg/day in week 1 and increasing to 50 μg/day in week 2). Response was defined categorically as 50% reduction and total score less than 15 in 21-item Hamilton Rating Scale for Depression (HRSD-21) at week 8 and remission as HRSD-21 less than 8. Results: There was no difference between treatment groups at final assessment; 65% of placebo and 61.8% of T3 treated subjects achieved response and 50.6% of placebo and 40.8% of T3 treated patients achieved remission. The mean daily dose at final assessment of sertraline and T3, respectively was 144.7 mg (±48.7 mg) and 48.2 μg (±7 μg). Median time to response did not differ between treatment groups. Baseline thyroid function tests did not predict response to sertraline treatment or T3 augmentation. Conclusions: These results do not support the routine use of T3 to enhance or accelerate onset of antidepressant response in patients with major depressive disorder (Clinical Trials.gov: NCT00208702).

Original languageEnglish
Pages (from-to)1406-1413
Number of pages8
JournalJournal of Psychiatric Research
Volume46
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Sertraline
Major Depressive Disorder
Triiodothyronine
Placebos
Antidepressive Agents
Therapeutics
Thyroid Function Tests
Diagnostic and Statistical Manual of Mental Disorders
Outpatients
Randomized Controlled Trials
Placebo
Clinical Trials
Depression

Keywords

  • Antidepressant
  • Augmentation
  • Depression
  • Remission
  • Response
  • Triiodothyronine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Arts and Humanities (miscellaneous)

Cite this

The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. / Garlow, Steven J.; Dunlop, Boadie W.; Ninan, Philip T.; Nemeroff, Charles.

In: Journal of Psychiatric Research, Vol. 46, No. 11, 01.11.2012, p. 1406-1413.

Research output: Contribution to journalArticle

@article{c329809fb9e4448983b464dfe3359305,
title = "The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder",
abstract = "Objective: To determine whether the combination of triiodothyronine (T3) plus sertraline at treatment initiation confers greater antidepressant efficacy than sertraline plus placebo in patients with major depressive disorder. Method: Eight-week, double blind, randomized placebo controlled clinical trial of 153 adult outpatients between 18 and 60 years of age, with DSM-IV defined major depressive disorder. Patients were treated with sertraline flexibly adjusted for tolerability and in a double blind fashion with placebo or T3 (25 μg/day in week 1 and increasing to 50 μg/day in week 2). Response was defined categorically as 50{\%} reduction and total score less than 15 in 21-item Hamilton Rating Scale for Depression (HRSD-21) at week 8 and remission as HRSD-21 less than 8. Results: There was no difference between treatment groups at final assessment; 65{\%} of placebo and 61.8{\%} of T3 treated subjects achieved response and 50.6{\%} of placebo and 40.8{\%} of T3 treated patients achieved remission. The mean daily dose at final assessment of sertraline and T3, respectively was 144.7 mg (±48.7 mg) and 48.2 μg (±7 μg). Median time to response did not differ between treatment groups. Baseline thyroid function tests did not predict response to sertraline treatment or T3 augmentation. Conclusions: These results do not support the routine use of T3 to enhance or accelerate onset of antidepressant response in patients with major depressive disorder (Clinical Trials.gov: NCT00208702).",
keywords = "Antidepressant, Augmentation, Depression, Remission, Response, Triiodothyronine",
author = "Garlow, {Steven J.} and Dunlop, {Boadie W.} and Ninan, {Philip T.} and Charles Nemeroff",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.jpsychires.2012.08.009",
language = "English",
volume = "46",
pages = "1406--1413",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder

AU - Garlow, Steven J.

AU - Dunlop, Boadie W.

AU - Ninan, Philip T.

AU - Nemeroff, Charles

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Objective: To determine whether the combination of triiodothyronine (T3) plus sertraline at treatment initiation confers greater antidepressant efficacy than sertraline plus placebo in patients with major depressive disorder. Method: Eight-week, double blind, randomized placebo controlled clinical trial of 153 adult outpatients between 18 and 60 years of age, with DSM-IV defined major depressive disorder. Patients were treated with sertraline flexibly adjusted for tolerability and in a double blind fashion with placebo or T3 (25 μg/day in week 1 and increasing to 50 μg/day in week 2). Response was defined categorically as 50% reduction and total score less than 15 in 21-item Hamilton Rating Scale for Depression (HRSD-21) at week 8 and remission as HRSD-21 less than 8. Results: There was no difference between treatment groups at final assessment; 65% of placebo and 61.8% of T3 treated subjects achieved response and 50.6% of placebo and 40.8% of T3 treated patients achieved remission. The mean daily dose at final assessment of sertraline and T3, respectively was 144.7 mg (±48.7 mg) and 48.2 μg (±7 μg). Median time to response did not differ between treatment groups. Baseline thyroid function tests did not predict response to sertraline treatment or T3 augmentation. Conclusions: These results do not support the routine use of T3 to enhance or accelerate onset of antidepressant response in patients with major depressive disorder (Clinical Trials.gov: NCT00208702).

AB - Objective: To determine whether the combination of triiodothyronine (T3) plus sertraline at treatment initiation confers greater antidepressant efficacy than sertraline plus placebo in patients with major depressive disorder. Method: Eight-week, double blind, randomized placebo controlled clinical trial of 153 adult outpatients between 18 and 60 years of age, with DSM-IV defined major depressive disorder. Patients were treated with sertraline flexibly adjusted for tolerability and in a double blind fashion with placebo or T3 (25 μg/day in week 1 and increasing to 50 μg/day in week 2). Response was defined categorically as 50% reduction and total score less than 15 in 21-item Hamilton Rating Scale for Depression (HRSD-21) at week 8 and remission as HRSD-21 less than 8. Results: There was no difference between treatment groups at final assessment; 65% of placebo and 61.8% of T3 treated subjects achieved response and 50.6% of placebo and 40.8% of T3 treated patients achieved remission. The mean daily dose at final assessment of sertraline and T3, respectively was 144.7 mg (±48.7 mg) and 48.2 μg (±7 μg). Median time to response did not differ between treatment groups. Baseline thyroid function tests did not predict response to sertraline treatment or T3 augmentation. Conclusions: These results do not support the routine use of T3 to enhance or accelerate onset of antidepressant response in patients with major depressive disorder (Clinical Trials.gov: NCT00208702).

KW - Antidepressant

KW - Augmentation

KW - Depression

KW - Remission

KW - Response

KW - Triiodothyronine

UR - http://www.scopus.com/inward/record.url?scp=84866911116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866911116&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2012.08.009

DO - 10.1016/j.jpsychires.2012.08.009

M3 - Article

C2 - 22964160

AN - SCOPUS:84866911116

VL - 46

SP - 1406

EP - 1413

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

IS - 11

ER -